Table 2 Association between PTX3 levels and presence of pre-eclampsia and HELLP syndrome

From: Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study

Progressive adjustment

Controls

PE

HELLP

OR PE (95% CI)

p value

OR HELLP (95% CI)

p value

Unadjusted

461

368

195

1.04 (1.02; 1.07)

<0.001

1.08 (1.05; 1.11)

<0.001

Plus maternal age

461

368

195

1.04 (1.02; 1.07)

<0.001

1.09 (1.05; 1.12)

<0.001

Plus recruitment place

457

366

195

1.05 (1.02; 1.08)

<0.001

1.10 (1.06; 1.13)

<0.001

Plus recruitment date

461

368

195

1.05 (1.03; 1.08)

<0.001

1.10 (1.06; 1.14)

<0.001

Plus ethnicity

457

366

193

1.05 (1.03; 1.08)

<0.001

1.10 (1.06; 1.14)

<0.001

Plus PE family history

457

366

193

1.05 (1.02; 1.08)

<0.001

1.10 (1.06; 1.13)

<0.001

Plus smoking

453

360

190

1.05 (1.02; 1.08)

<0.001

1.10 (1.06; 1.14)

<0.001

Plus low SES

439

339

177

1.05 (1.02; 1.08)

<0.001

1.10 (1.07; 1.14)

<0.001

Pus BMI

395

294

145

1.05 (1.02; 1.09)

<0.001

1.12 (1.08; 1.17)

<0.001

Plus gestational age

395

292

142

1.06 (1.03; 1.09)

<0.001

1.13 (1.08; 1.18)

<0.001

Plus multiple pregnancy

395

292

142

1.06 (1.03; 1.10)

<0.001

1.13 (1.08; 1.18)

<0.001

  1. SES socioeconomic status, BMI body mass index
  2. OR estimated with multinomial regression analysis. OR indicates the change in odds of pre-eclampsia or HELLP syndrome for increase in one unit of PTX3 levels
Back to article page